Its predecessor (former Shijiazhuang No.1 Pharmaceutical Factory) was founded in 1938, with a development history of 70 years, which has made outstanding contributions to the liberation of China people and the medical and health undertakings in new China.
Company listed in Hong Kong (0 1093. HK) was selected as a constituent stock of Hang Seng Index, and on behalf of China Pharmaceutical, it was selected as the 23rd in the list of global pharmaceutical companies' R&D pipelines, serving patients all over the world.
The production scope of the company's products
The production scope covers seven therapeutic fields, more than 400 kinds of preparation products and more than 20 kinds of chemical synthetic raw materials. At the same time, it is equipped with international advanced automatic production lines such as Bosch, Fete, ullman, GEA and IMA. The comprehensive annual production capacity of solid preparations is 654.38+0.5 billion tablets, and the annual production capacity of APIs is 654.38+0.5 million tons. The main preparation products are Xuanning and IMA. The main raw materials are azithromycin, indomethacin, levoamlodipine maleate, tramadol hydrochloride and imatinib mesylate.
Business scope of the company
The production and sale of drugs (operated according to the Pharmaceutical Production License); Sales of chemical raw materials (excluding dangerous chemicals and other administrative licensing projects); Development of medical technology; To engage in the export business of self-produced products and related technologies of the enterprise, and to engage in the import and export business of raw and auxiliary materials, instruments and meters, spare parts of machinery and equipment and related technologies needed by the enterprise for production and scientific research (except for commodities and technologies restricted or prohibited by the state); Marketing service; Road freight transport (excluding dangerous goods). (Projects subject to approval according to law can only be operated after approval by relevant departments)
Company product structure
The company has four pharmaceutical preparation production plants designed according to GMP standards and four API production lines with international advanced level. The main preparation products are Ou Yi, Wei Hong, Chimaite, Gubang, Qingrejiedu Soft Capsule, Xuanning and more than 200 kinds of preparations and health foods. Product forms include small-volume injections, powder injections, freeze-dried powder injections, tablets, hard capsules, soft capsules, granules and dry suspensions.
The honor of the company
By participating in global innovation, Shi Yao continuously provides better innovation results for human health. Establish a diversified product system and deepen the cultivation of Chinese medicine, raw materials and functional food; And actively put into prevention and treatment in COVID-19, the group's mRNA COVID-19 vaccine product is the first COVID-19 vaccine independently developed by China and obtained emergency authorization. In the field of cardiovascular and cerebrovascular diseases and anti-tumor, innovative drugs such as Enbipu, Mingfule, Duoenyi, Jinlitai, Haiyitan, Duoenda and Ouyuexin have been listed. Enbip, Xuanning and Jin Youli all won the second prize of National Science and Technology Progress Award, which is the highest national award in the field of medicine.
202 1, 10, 1 1 was selected as "Top 100 Innovative Enterprises of Strategic Emerging Industries in Hebei Province in 20021year" issued by Hebei High-tech Industry Association.